These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 26431823)

  • 1. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.
    Rakoczy EP; Lai CM; Magno AL; Wikstrom ME; French MA; Pierce CM; Schwartz SD; Blumenkranz MS; Chalberg TW; Degli-Esposti MA; Constable IJ
    Lancet; 2015 Dec; 386(10011):2395-403. PubMed ID: 26431823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration.
    Constable IJ; Pierce CM; Lai CM; Magno AL; Degli-Esposti MA; French MA; McAllister IL; Butler S; Barone SB; Schwartz SD; Blumenkranz MS; Rakoczy EP
    EBioMedicine; 2016 Dec; 14():168-175. PubMed ID: 27865764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial.
    Constable IJ; Lai CM; Magno AL; French MA; Barone SB; Schwartz SD; Blumenkranz MS; Degli-Esposti MA; Rakoczy EP
    Am J Ophthalmol; 2017 May; 177():150-158. PubMed ID: 28245970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.
    Heier JS; Kherani S; Desai S; Dugel P; Kaushal S; Cheng SH; Delacono C; Purvis A; Richards S; Le-Halpere A; Connelly J; Wadsworth SC; Varona R; Buggage R; Scaria A; Campochiaro PA
    Lancet; 2017 Jul; 390(10089):50-61. PubMed ID: 28526489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy for Age-Related Macular Degeneration.
    Constable IJ; Blumenkranz MS; Schwartz SD; Barone S; Lai CM; Rakoczy EP
    Asia Pac J Ophthalmol (Phila); 2016; 5(4):300-3. PubMed ID: 27488071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration.
    Rakoczy EP; Magno AL; Lai CM; Pierce CM; Degli-Esposti MA; Blumenkranz MS; Constable IJ
    Am J Ophthalmol; 2019 Aug; 204():113-123. PubMed ID: 30878487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
    Campochiaro PA; Avery R; Brown DM; Heier JS; Ho AC; Huddleston SM; Jaffe GJ; Khanani AM; Pakola S; Pieramici DJ; Wykoff CC; Van Everen S
    Lancet; 2024 Apr; 403(10436):1563-1573. PubMed ID: 38554726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
    Koss MJ; Scholtz S; Haeussler-Sinangin Y; Singh P; Koch FH
    Ophthalmologica; 2010; 224(2):72-8. PubMed ID: 19707030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD.
    Eldem BM; Muftuoglu G; Topbaş S; Çakir M; Kadayifcilar S; Özmert E; Bahçecioğlu H; Sahin F; Sevgi S;
    Acta Ophthalmol; 2015 Sep; 93(6):e458-64. PubMed ID: 25160859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.
    Holz FG; Dugel PU; Weissgerber G; Hamilton R; Silva R; Bandello F; Larsen M; Weichselberger A; Wenzel A; Schmidt A; Escher D; Sararols L; Souied E
    Ophthalmology; 2016 May; 123(5):1080-9. PubMed ID: 26906165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
    Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of core vitrectomy in the treatment of age-related macular degeneration.
    Schramm K; Mueller M; Koch FH; Singh P; Kohnen T; Koss MJ
    Acta Ophthalmol; 2014 Aug; 92(5):465-72. PubMed ID: 24690440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
    Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
    Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.